公开(公告)号：WO2009070761A1

公开(公告)日：2009-06-04

申请号：PCT/US2008/085030

申请日：2008-11-26

Applicant: CELATOR PHARMACEUTICALS, INC ,  ANSELL, Steven, M. ,  JOHNSTONE, Sharon ,  TARDI, Paul ,  MAYER, Lawrence

Inventor： ANSELL, Steven, M. ,  JOHNSTONE, Sharon ,  TARDI, Paul ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/1075 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/337 ,  A61K47/543 ,  C07D305/14

Abstract: Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.

Abstract translation: 描述了通过乙醇酸酯连接体与通过疏水部分偶联的紫杉烷形成的用于递送紫杉烷结合物前药的纳米颗粒制剂。

公开(公告)号：WO2007035783A3

公开(公告)日：2007-11-08

申请号：PCT/US2006036569

申请日：2006-09-19

Applicant: CELATOR PHARMACEUTICALS INC ,  JOHNSTONE SHARON ,  HARVIE PIERROT ,  TARDI PAUL ,  HARASYM TROY ,  MAYER LAWRENCE

Inventor： JOHNSTONE SHARON ,  HARVIE PIERROT ,  TARDI PAUL ,  HARASYM TROY ,  MAYER LAWRENCE

IPC: A61K31/724 ,  C07F15/00

CPC classification number: A61K9/127

Abstract: Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

Abstract translation: 包含与其稳定结合的胞苷类似物和铂剂的递送载体的组合物在施用这些药物的组合时可用于实现增强的治疗效果。

公开(公告)号：WO2006055903B1

公开(公告)日：2006-08-10

申请号：PCT/US2005042131

申请日：2005-11-18

Applicant: CELATOR PHARMACEUTICALS INC ,  TARDI PAUL ,  WEBB MURRAY ,  JOHNSTONE SHARON ,  HARVIE PIERROT ,  MAYER LAWRENCE

Inventor： TARDI PAUL ,  WEBB MURRAY ,  JOHNSTONE SHARON ,  HARVIE PIERROT ,  MAYER LAWRENCE

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/1278

Abstract: This invention relates to encapsulation of drugs and other agents into preformed delivery vehicles.

Abstract translation: 本发明涉及将药物和其它药剂包封到预成型递送载体中。

公开(公告)号：WO2006081354A2

公开(公告)日：2006-08-03

申请号：PCT/US2006002782

申请日：2006-01-26

Applicant: CELATOR PHARMACEUTICALS INC ,  TARDI PAUL ,  MAYER LAWRENCE ,  CABRAL-LILLY DONNA

Inventor： TARDI PAUL ,  MAYER LAWRENCE ,  CABRAL-LILLY DONNA

CPC classification number: A61K9/127 ,  A61K9/1277

Abstract: The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.

Abstract translation: 本发明涉及降低凝胶相脂质递送载体群体的多分散性的方法。

公开(公告)号：WO2017083592A1

公开(公告)日：2017-05-18

申请号：PCT/US2016/061444

申请日：2016-11-10

Applicant: CELATOR PHARMACEUTICALS, INC. ,  OREGON HEALTH & SCIENCES UNIVERSITY

Inventor： GORDON, Max ,  TARDI, Paul ,  TYNER, Jeffrey ,  MAYER, Lawrence

IPC: A61K31/00 ,  A61P35/00 ,  A61P35/02 ,  C12Q1/68

CPC classification number: A61K31/7068 ,  A61K31/44 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/704 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

Abstract translation: 用于鉴定适于用CPX-351治疗的携带癌症的受试者的诊断方法包括来自候选受试者的细胞的遗传和离体测试。 与CPX-351和FLT-3抑制剂联合治疗可改善CPX-351摄取和毒性。

公开(公告)号：WO2013059133A1

公开(公告)日：2013-04-25

申请号：PCT/US2012/060293

申请日：2012-10-15

Applicant: CELATOR PHARMACEUTICALS INC.

Inventor： CABRAL-LILLY, Donna ,  MAYER, Lawrence ,  TARDI, Paul ,  WATKINS, David ,  ZENG, Yi

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/19 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K47/26

Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Abstract translation: 公开了具有两种或多种包封的药物的冻干脂质体制剂。 这些制剂显示优异的药物保留特征，并且还保持冻干和重构后的尺寸分布。

公开(公告)号：WO2008101214A3

公开(公告)日：2008-08-21

申请号：PCT/US2008/054168

申请日：2008-02-15

Applicant: CELATOR PHARMACEUTICALS, INC. ,  LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

Inventor： LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

IPC: A01N43/04 ,  A61K31/70

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

公开(公告)号：WO2007050784A3

公开(公告)日：2007-06-14

申请号：PCT/US2006041832

申请日：2006-10-25

Applicant: CELATOR PHARMACEUTICALS INC ,  BATIST GERALD ,  MAYER LAWRENCE ,  SWENSON CHRISTINE ,  JANOFF ANDREW ,  GELMON KAREN

Inventor： BATIST GERALD ,  MAYER LAWRENCE ,  SWENSON CHRISTINE ,  JANOFF ANDREW ,  GELMON KAREN

IPC: A61K31/4745 ,  A61K31/505 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61K31/505

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors.

Abstract translation: 本文提供了通过施用包含固定的非拮抗摩尔比的伊立替康和氟尿苷的药物组合物治疗癌症的方法。 这种方法在治疗晚期实体瘤的癌症患者中特别有用。

公开(公告)号：WO2005102359A1

公开(公告)日：2005-11-03

申请号：PCT/CA2005/000625

申请日：2005-04-22

Applicant: CELATOR PHARMACEUTICALS, INC. ,  MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

Inventor： MAYER, Lawrence ,  JOHNSTONE, Sharon ,  HARASYM, Troy

IPC: A61K31/7068

CPC classification number: A61K9/127 ,  A61K9/1278 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  Y10S977/801 ,  A61K2300/00

Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in a liposomal carrier. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carrier are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

Abstract translation: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素，多柔比星和伊达比星组，而优选的胞苷类似物选自阿糖胞苷，吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

公开(公告)号：WO2023288103A1

公开(公告)日：2023-01-19

申请号：PCT/US2022/037374

申请日：2022-07-15

Applicant: CELATOR PHARMACEUTICALS, INC.

Inventor： TARDI, Paul ,  WAN, Leon ,  GARG, Shyam Madhusudan ,  GAO, Jun ,  LEGROS, Philippe

IPC: A61K9/127 ,  A61K9/10 ,  A61K9/00 ,  A61K31/00

Abstract: Provided herein are methods of purifying liposomal formulations by washing with acidic aqueous solutions.